Notice to 340B Covered Entities Regarding Uplizna™ (inebilizumab-cdon) Limited Distribution Network

July 29, 2020

This notice provides information for 340B covered entities regarding the distribution of Uplizna™ (inebilizumab-cdon). Uplizna™ (inebilizumab-cdon) is a designated orphan drug, and Viela Bio, therefore, distributes Uplizna™(inebilizumab-cdon) to 340B covered entities through a single authorized specialty distributor that is equipped to successfully facilitate access.

| Uplizna™ (inebilizumab-cdon) | 72677-551-01 | three 100mg vials/300 mg carton |

To obtain Uplizna™ (inebilizumab-cdon), 340B covered entities should contact Cardinal Health Specialty Distribution:

Email: Multi-Specialty-Priority@cardinalhealth.com
www.cardinalhealth.com/spd

The distribution model described above is consistent with section 340B(a)(1) of the Public Health Service Act, which requires manufacturers to “offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.”

If you have any questions regarding access to Uplizna™ (inebilizumab-cdon), please contact Paul Sparks at 512-667-5031.